Regulus Therapeutics Insider Neil W. Gibson Unloads 1,100 Shares (RGLS)
Regulus Therapeutics (NASDAQ:RGLS) Insider Neil W. Gibson unloaded 1,100 shares of the stock on the open market in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $8.03, for a total transaction of $8,833.00. Following the transaction, the insider now directly owns 50,000 shares of the company’s stock, valued at approximately $401,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Regulus Therapeutics (NASDAQ:RGLS) traded up 3.86% during mid-day trading on Friday, hitting $8.205. 421,766 shares of the company’s stock traded hands. Regulus Therapeutics has a one year low of $4.70 and a one year high of $12.89. The stock’s 50-day moving average is $6.8 and its 200-day moving average is $8.40. The company’s market cap is $342.8 million.
A number of analysts have recently weighed in on RGLS shares. Analysts at Cowen and Company reiterated an “outperform” rating on shares of Regulus Therapeutics in a research note to investors on Thursday, November 14th. Separately, analysts at FBR & Co. initiated coverage on shares of Regulus Therapeutics in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of Regulus Therapeutics in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Seven investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $14.75.
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.